Opthea Q&A Sep 2024 Update, page-25

	Year/Month	Event/Activity
1	1984	Company Founded - Opthea was originally established as Circadian Technologies Limited.
2	2015	Company Rebranding - Opthea shifted its focus primarily to developing treatments for retinal diseases such as Wet AMD.
3	2018-2020	Phase 1/2a Trials (Sozinibercept) - Early clinical trials began to assess safety and efficacy in combination with anti-VEGF therapies.
4	2021-2022	Phase 2b Trials - Enrolled 366 Wet AMD patients. Top-line data: +5.7 letter improvement in BCVA at 24 weeks.
5	September 2023	Capital Raising - Issued 160 million shares to institutional investors and 16 million shares to retail investors, raising A$82 million.
6	December 2023	Amended DFA with Carlyle/Abingworth - Provided US$170 million in non-equity funding.
7	February 2024	Phase 3 COAST Trial Enrollment Complete - 998 patients enrolled.
8	May 2024	Phase 3 SHORE Trial Enrollment Complete - 986 patients enrolled.
9	June 2024	Capital Raising - Issued shares to raise A$171.5 million, with an additional retail component raising A$55.9 million.
10	April 2025	Top-line Data (COAST Trial) - Expected release of 52-week safety and efficacy results.
11	July-August 2025	Top-line Data (SHORE Trial) - Expected release of 52-week safety and efficacy results.
12	September 2025	OPTOA Options Expiry - OPTOA options (A$0.80 exercise price) expire.
13	April 2026	12-Month Safety Review (COAST Trial) - Long-term safety review of COAST trial.
14	June 2026	OPTOB Options Expiry - OPTOB options (A$1.00 exercise price) expire.
15	July-August 2026	12-Month Safety Review (SHORE Trial) - Long-term safety review of SHORE trial.
16	Mid to Late 2026	FDA Approval (Potential) - Sozinibercept could be approved for U.S. market entry.
17	Mid to Late 2026	Capital Raising (for Commercialization) - Expected capital raise to fund commercialization.
18	Late 2026 - Early 2027	Commercialization (Sozinibercept) - Sozinibercept could enter the U.S. market following FDA approval.

Thanks, Pigrace! While I did build a knowledge base using GPT with public info on Opthea, the validation were done by me so got the date wrong.I've now improved the wording and included the long-term safety review, which happens 12 months after the topline results. I’ve also updated the SHORE topline readout timeline to allow an extra month for data analysis.Are there any other key dates that are wrong or missing?